caffeine and rifampin

caffeine has been researched along with rifampin in 37 studies

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19903 (8.11)18.7374
1990's4 (10.81)18.2507
2000's9 (24.32)29.6817
2010's18 (48.65)24.3611
2020's3 (8.11)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choo, YM; Doerksen, RJ; Gertsch, J; Hamann, MT; Jacob, MR; Khan, SI; Kudrimoti, S; Madgula, V; Mayer, AM; Odde, S; Peng, J; Pennaka, HK; Prasanna, S; Rao, KV; Tekwani, BL; Tu, LC; Wang, B1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Glen, RC; Lowe, R; Mitchell, JB1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Myers, DK1
Gibaldi, M1
Polk, RE1
Gillies, NE; Marshall, NJ; Panchapagesan, G1
Generet, K; Marschall, HU; Matern, S; Wietholtz, H; Zysset, T1
Gibson, GG; Goldfarb, PS; Gray, TJ; Ogg, MS; Tarbit, M; Williams, JM1
Arold, G; Bauer, S; Brockmöller, J; Roots, I; Schmider, J1
Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW1
Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C1
Backman, JT; Granfors, MT; Neuvonen, PJ1
Andersson, TB; Bäckström, T; Bertilsson, L; Böttiger, Y; Bredberg, E; Diczfalusy, U; Kanebratt, KP; Sparve, E1
Abuznait, AH; Burk, D; Cain, C; Ingram, D; Kaddoumi, A1
Abuznait, AH; Kaddoumi, A; Patrick, SG1
Abuznait, AH; Hill, RA; Kaddoumi, A; Qosa, H1
Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H1
Chang, ZQ; Li, J; Zhai, QQ1
Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H1
Hopkins, A; Marshall, JC; Miners, JO; Rowland, A; Sorich, MJ; van Dyk, M; Wood, LS1
Chakraborty, A; Dhuria, SV; Elmeliegy, M; He, H; Heimbach, T; Huth, F; Ji, Y; Miller, M; Samant, TS; Schiller, H; Umehara, K1
Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW1

Reviews

4 review(s) available for caffeine and rifampin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
Drug interactions: Part I.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:5

    Topics: Antidepressive Agents, Tricyclic; Caffeine; Cimetidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Fluconazole; Fluoxetine; Hexobarbital; Humans; Ketoconazole; Nimodipine; Oxidoreductases; Pharmaceutical Preparations; Rifampin; Stereoisomerism; Warfarin; Zidovudine

1992
Drug-drug interactions with ciprofloxacin and other fluoroquinolones.
    The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A

    Topics: Antacids; Caffeine; Ciprofloxacin; Cyclosporins; Drug Interactions; Humans; Intestinal Absorption; Rifampin; Theophylline

1989

Trials

6 trial(s) available for caffeine and rifampin

ArticleYear
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
    Pharmacogenetics, 1999, Volume: 9, Issue:6

    Topics: Adult; Alprazolam; Area Under Curve; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Mixed Function Oxygenases; Reference Values; Rifampin

1999
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:8

    Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger

2005
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Blood Pressure; Caffeine; Clonidine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Drug Interactions; Enzyme Induction; Female; Heart Rate; Humans; Male; Rifampin

2006
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
    Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:5

    Topics: Adult; Anti-Ulcer Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Antimalarials; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Drug Combinations; Enzyme Induction; Female; Humans; Hydroxycholesterols; Losartan; Male; Middle Aged; Omeprazole; Quinine; Rifampin

2008
Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:9

    Topics: Adult; Biomarkers; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Diet; Genotype; Humans; Male; Midazolam; Phenotype; Racial Groups; Rifampin; Uric Acid; Young Adult

2019
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:3

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Biotransformation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Midazolam; Models, Theoretical; Patient Safety; Purines; Rifampin; Risk Assessment; Ritonavir

2020

Other Studies

27 other study(ies) available for caffeine and rifampin

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
    Journal of medicinal chemistry, 2010, Jan-14, Volume: 53, Issue:1

    Topics: Animals; Anti-Infective Agents; Carbazoles; Cerebellar Diseases; Indole Alkaloids; Mice; Microbial Sensitivity Tests; Molecular Structure; Neurogenic Inflammation; Porifera; Stereoisomerism; Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Inhibition and amplification of the radiation-induced degradation of DNA in Escherichia coli.
    Canadian journal of microbiology, 1975, Volume: 21, Issue:1

    Topics: Caffeine; DNA Repair; DNA, Bacterial; Dose-Response Relationship, Radiation; Energy Metabolism; Escherichia coli; Hydrazones; Mutation; Nitriles; Phenylhydrazines; Radiation Effects; Rifampin; Thymidine; Tritium

1975
Rescue by chloramphenicol and rifampicin of UV-irradiated lon, exrA and recA mutants of Escherichia coli K12.
    Mutation research, 1973, Volume: 19, Issue:2

    Topics: Caffeine; Cell Survival; Chloramphenicol; Escherichia coli; Methoxsalen; Mutation; Radiation Effects; Rifampin; Ultraviolet Rays

1973
The influence of rifampin treatment on caffeine clearance in healthy man.
    Journal of hepatology, 1995, Volume: 22, Issue:1

    Topics: Caffeine; Enzyme Induction; Female; Half-Life; Humans; Male; Microsomes, Liver; Osmolar Concentration; Reference Values; Rifampin

1995
A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.
    Xenobiotica; the fate of foreign compounds in biological systems, 1999, Volume: 29, Issue:3

    Topics: Alkaline Phosphatase; beta-Naphthoflavone; Caffeine; Carbamazepine; Carcinoma, Hepatocellular; Clofibrate; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation; Genes, Reporter; Glucocorticoids; Hormone Antagonists; Humans; Isoniazid; Mifepristone; Mixed Function Oxygenases; Phenobarbital; Phenylbutazone; Phenytoin; Receptors, Glucocorticoid; Recombinant Proteins; Rifampin; Tumor Cells, Cultured; Xenobiotics

1999
In vivo modulation of CYP enzymes by quinidine and rifampin.
    Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:4

    Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline

2000
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:8

    Topics: Alzheimer Disease; Amyloid beta-Peptides; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cell Line; Central Nervous System Agents; Dexamethasone; Estradiol; Humans; Pentylenetetrazole; Phloroglucinol; Rifampin; Staining and Labeling; Terpenes; Up-Regulation; Verapamil

2011
Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2011, Volume: 14, Issue:2

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cell Line, Tumor; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Gene Expression; Humans; Pentylenetetrazole; Pharmaceutical Preparations; Phloroglucinol; Rhodamine 123; Rifampin; Stimulation, Chemical; Terpenes; Up-Regulation; Verapamil

2011
Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2012, Volume: 31, Issue:1

    Topics: Amyloid beta-Peptides; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caffeine; Carbon Isotopes; Endothelial Cells; Enzyme Inhibitors; Inulin; Low Density Lipoprotein Receptor-Related Protein-1; Mice; Mice, Inbred C57BL; Microvessels; Peptide Fragments; Receptors, LDL; Rifampin; RNA, Messenger; Tumor Suppressor Proteins; Up-Regulation

2012
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
    Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:6

    Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment

2013
Evaluation on activity of cytochrome p450 enzymes in turbot via a probe drug cocktail.
    Journal of aquatic animal health, 2014, Volume: 26, Issue:4

    Topics: Animals; Antitubercular Agents; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Induction; Flatfishes; Folic Acid Antagonists; Muscle Relaxants, Central; Nucleic Acid Synthesis Inhibitors; Phosphodiesterase Inhibitors; Rifampin

2014
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
    Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:7

    Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin

2018
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Antimicrobial agents and chemotherapy, 2023, 10-18, Volume: 67, Issue:10

    Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary

2023
chemdatabank.com